Evercore ISI lowered the firm’s price target on TransMedics (TMDX) to $118 from $170 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics: Strengthening High-Conviction Buy on Robust Growth Outlook, Next-Gen Platforms, and International Expansion Upside
- Reiterating Buy on TransMedics: Defensible OCS Leadership and Organ Management Expansion Drive Sustained Growth Outlook
- TransMedics: Early 2026 DCD and Liver Transplant Momentum Supports Upside and Maintained Buy Rating
- TransMedics price target raised to $130 from $115 at Stifel
- TransMedics Group Signals Strong Growth in Earnings Call